- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: miRNAs.
Displaying page 1 of 2.
EudraCT Number: 2018-004063-31 | Sponsor Protocol Number: FIM-PRELEVD-2018-01 | Start Date*: 2019-04-26 |
Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) | ||
Full Title: Mechanisms of cardio and nephroprotection in patients who are going on cardiac surgery with right ventricular dysfunction, with preoperative treatment of levosimendan compared with placebo. (PREL... | ||
Medical condition: Perioperative right ventricle dysfunction | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000077-39 | Sponsor Protocol Number: RECOGITO_V1.0_2014 | Start Date*: 2014-02-27 | |||||||||||||||||||||
Sponsor Name:Sapienza University of Rome | |||||||||||||||||||||||
Full Title: Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phospho... | |||||||||||||||||||||||
Medical condition: Diabetic Cardiomyopathy, Diabetes Mellitus Type 2, Left Ventricular Hypertrophy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000784-16 | Sponsor Protocol Number: NCPACI | Start Date*: 2016-04-15 |
Sponsor Name:Akershus University Hospital | ||
Full Title: Focal cartilage defects in the knee – A randomized controlled trial comparing Autologous Chondrocyte Implantation with arthroscopic debridement | ||
Medical condition: Symptomatic focal cartilage defects in the knee | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002643-28 | Sponsor Protocol Number: CA209-8JD | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. | |||||||||||||
Medical condition: Stage III/IV resectable oral squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004141-17 | Sponsor Protocol Number: | Start Date*: 2020-08-07 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Children's Oncology Group | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Ovarian, Testicular, or Extragonadal germ cell tumours | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001264-38 | Sponsor Protocol Number: MOU-2017-01 | Start Date*: 2017-10-16 |
Sponsor Name:Masaryk Memorial Cancer Institute | ||
Full Title: Sequential FDG-PET and Plasma/Tissue miRNA as a Biomarkers of Preoperative Treatment Strategy in Locally Advanced Oesophago-Gastric Cancer | ||
Medical condition: locally advanced resectable oesophago-gastric adenocarcinoma (Siewert I – III) with T3N0, T4N0, T2 – T4N+, stage Ib – IIIc | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005189-39 | Sponsor Protocol Number: 11-10 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer. | |||||||||||||
Medical condition: HER2-positive metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) FI (Completed) PT (Completed) ES (Temporarily Halted) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002563-25 | Sponsor Protocol Number: VEGF-RTX-2013 | Start Date*: 2014-01-13 | ||||||||||||||||
Sponsor Name:VU University Medical Centre | ||||||||||||||||||
Full Title: Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma | ||||||||||||||||||
Medical condition: Angiogenesis in esophageal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001617-14 | Sponsor Protocol Number: CRLX030A2205 | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia | |||||||||||||
Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004497-15 | Sponsor Protocol Number: ERGO | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C... | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004983-37 | Sponsor Protocol Number: FFIS-INM-2017-04 | Start Date*: 2018-10-16 |
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia | ||
Full Title: Multicenter, randomized, prospective study to establish the clinical efficacy and the mechanisms of tolerance following immunosuppression withdrawal in liver transplantation | ||
Medical condition: Hepatic transplant | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004078-16 | Sponsor Protocol Number: DOSCORT20092231 | Start Date*: 2020-11-23 |
Sponsor Name:Sahlgrenska University Hospital, Gothenburg | ||
Full Title: A dose-response study of markers of glucocorticoid action (DOSCORT)- A double-blind, randomized, two-period, two-dose, cross-over study in subjects with primary adrenal insufficiency | ||
Medical condition: Adrenal insufficiency e.g. Addison´s disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002936-26 | Sponsor Protocol Number: 17-157 | Start Date*: 2019-11-28 |
Sponsor Name:Heinrich-Heine-University Düsseldorf | ||
Full Title: Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma | ||
Medical condition: Patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005017-31 | Sponsor Protocol Number: DERN | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | |||||||||||||
Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY | |||||||||||||
Medical condition: advanced or metastatic Nose Pharynx Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004997-27 | Sponsor Protocol Number: OBELICS | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
Full Title: Randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer | |||||||||||||
Medical condition: patients with metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002564-24 | Sponsor Protocol Number: B490 | Start Date*: 2011-10-14 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer | |||||||||||||
Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002530-50 | Sponsor Protocol Number: EspeRare_RIM_001 | Start Date*: 2015-11-04 | |||||||||||
Sponsor Name:EspeRare | |||||||||||||
Full Title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004134-26 | Sponsor Protocol Number: sof-crio | Start Date*: 2015-02-19 | ||||||||||||||||
Sponsor Name:Centro Masve -Università degli Studi di Firenze-AOUC | ||||||||||||||||||
Full Title: A MULTICENTER, PROSPECTIVE, SINGLE ARM, OPEN-LABEL, PILOT STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF SOFOSBUVIR FOR SYMPTOMATIC MIXED CRYOGLOBULINEMIA | ||||||||||||||||||
Medical condition: HCV chronic hepatitis and Mixed Cryoglobulinemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005138-12 | Sponsor Protocol Number: BRCAP-GELTAMO12 | Start Date*: 2013-03-26 | |||||||||||
Sponsor Name:GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea) | |||||||||||||
Full Title: Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma. | |||||||||||||
Medical condition: Diffuse large B cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002911-23 | Sponsor Protocol Number: DS102A-08-CV2 | Start Date*: 2020-10-12 | ||||||||||||||||
Sponsor Name:Afimmune | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study to Assess the Mechanism of Action and Safety of Orally Administered Epeleuton in Patients with Type 2 Diabetes and Diabet... | ||||||||||||||||||
Medical condition: Type 2 diabetes and diabetic complications | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
